
|Articles|July 20, 2015
Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer
Author(s)Sunil Verma, MD, MSEd, FRCPC
Sunil Verma, MD, MSEd, FRCPC, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.
Advertisement
Sunil Verma, MD, MSEd, FRCPC, medical director, Louise Temerty Breast Cancer Centre at Sunnybrook Health Sciences Centre, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves TTFields Device With Chemo in Pancreatic Cancer
2
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers
3
Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates
4
FDA Approves Pembrolizumab Combination in Platinum-Resistant Ovarian Cancer
5




































